To appraise the clinical and cost effectiveness of pembrolizumab within its marketing authorisation for adjuvant treatment of melanoma with high risk of recurrence.
Status Proposed
Process STA

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
02 October 2017 - 31 October 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance